AR053053A1 - Vector - Google Patents

Vector

Info

Publication number
AR053053A1
AR053053A1 ARP060101428A ARP060101428A AR053053A1 AR 053053 A1 AR053053 A1 AR 053053A1 AR P060101428 A ARP060101428 A AR P060101428A AR P060101428 A ARP060101428 A AR P060101428A AR 053053 A1 AR053053 A1 AR 053053A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
acid molecule
control sequences
gamma
carboxylation
Prior art date
Application number
ARP060101428A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR053053A1 publication Critical patent/AR053053A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a una célula huésped que comprende un vector de expresion que comprende una molécula de ácido nucleico que codifica una proteína que requiere gamma-carboxilacion y secuencias de control de la expresion asociadas y una molécula de ácido nucleico que codifica una vitamina K epoxido reductasa y secuencias de control de la expresion asociadas y una molécula de ácido nucleico que codifica una gamma-glutamil carboxilasa y secuencias control asociadas. La presente se refiere además a un método para producir una proteína que requiere gamma-carboxilacion con altos rendimientos.
ARP060101428A 2005-04-13 2006-04-11 Vector AR053053A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500831 2005-04-13

Publications (1)

Publication Number Publication Date
AR053053A1 true AR053053A1 (es) 2007-04-18

Family

ID=37087286

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101428A AR053053A1 (es) 2005-04-13 2006-04-11 Vector

Country Status (17)

Country Link
US (3) US7989193B2 (es)
EP (1) EP1874928A1 (es)
JP (1) JP5461008B2 (es)
KR (2) KR101599062B1 (es)
CN (1) CN101198696B (es)
AR (1) AR053053A1 (es)
AU (1) AU2006234788B2 (es)
BR (1) BRPI0609120A2 (es)
CA (1) CA2602793C (es)
IL (1) IL186036A0 (es)
MX (1) MX2007012704A (es)
NO (1) NO20075088L (es)
NZ (1) NZ561925A (es)
RU (1) RU2415934C2 (es)
TW (1) TWI384070B (es)
WO (1) WO2006110083A1 (es)
ZA (1) ZA200708222B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101474A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP2336360A1 (en) 2003-09-23 2011-06-22 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP1874928A1 (en) 2005-04-13 2008-01-09 AstraZeneca AB A host cell comprising a vector for production of proteins requiring gamma-carboxylation
EP1963506B1 (en) 2005-12-02 2010-10-27 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
DK1969127T4 (en) * 2005-12-21 2017-10-16 Cnj Holdings Inc Process for the preparation of biologically active vitamin K-dependent proteins by recombinant methods
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP3009513A1 (en) * 2008-02-01 2016-04-20 Chromocell Corporation Novel cell lines and methods
EP2393930A4 (en) * 2009-02-02 2012-08-15 Chromocell Corp CELLULAR LINES EXPRESSING CFTR AND METHODS OF USE THEREOF
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
EP2816108A1 (en) * 2013-06-21 2014-12-24 Baxter International Inc Transformed fungus with vitamin K dependent activity
CN104293737B (zh) * 2014-09-16 2017-06-13 太原博奥特生物技术有限公司 一种包含表达功能性重组人凝血因子ⅶ载体的宿主细胞及其高水平表达方法
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN111239386B (zh) * 2020-01-20 2023-03-14 河南科技大学 一种靶向抑制维生素K依赖性γ-谷氨酰羧化酶的小分子化合物的筛选方法及应用
CN111154725A (zh) * 2020-01-20 2020-05-15 河南科技大学 一种用于筛选维生素k循环小分子抑制剂的双报告基因细胞体系、制备方法及其应用
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
KR102665227B1 (ko) * 2021-06-30 2024-05-10 씨제이제일제당 주식회사 고농도 l-글루탐산을 생산하기 위한 균주 및 이를 이용한 l-글루탐산 생산방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5118614A (en) 1988-01-18 1992-06-02 Tessek Sdruzeni Praha Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
AU8427091A (en) 1990-07-23 1992-02-18 Zymogenetics Inc. Gamma-carboxylase and methods of use
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
EP0796623B1 (de) 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
CA2315879A1 (en) 1997-12-24 1999-07-08 Immunex Corporation V201 dna and polypeptides
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
WO2001007068A1 (en) 1999-07-23 2001-02-01 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
AU2001268373A1 (en) 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
BR0114374A (pt) 2000-10-02 2003-12-30 Novo Nordisk As Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação
JP4150814B2 (ja) 2001-07-06 2008-09-17 財団法人化学及血清療法研究所 遺伝子組換えエカリン及びその製造方法
CN100347297C (zh) 2001-07-06 2007-11-07 财团法人化学及血清疗法研究所 利用基因工程技术制备人凝血酶的方法
CA2452395C (en) 2001-07-10 2012-04-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
EP2336360A1 (en) * 2003-09-23 2011-06-22 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
ES2344413T3 (es) 2003-10-14 2010-08-26 Baxter International Inc. Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP1676911B1 (en) 2003-10-24 2010-04-21 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Novel recombinant animal cells with high protein production, method of constructing the same and method of mass protein production using the same
EP1831363A1 (en) 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
EP1874928A1 (en) 2005-04-13 2008-01-09 AstraZeneca AB A host cell comprising a vector for production of proteins requiring gamma-carboxylation
EP1963506B1 (en) 2005-12-02 2010-10-27 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
DK1969127T4 (en) 2005-12-21 2017-10-16 Cnj Holdings Inc Process for the preparation of biologically active vitamin K-dependent proteins by recombinant methods
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
JP5461008B2 (ja) 2014-04-02
NO20075088L (no) 2007-11-12
US7989193B2 (en) 2011-08-02
US20120077229A1 (en) 2012-03-29
US20130065295A1 (en) 2013-03-14
US20080312127A1 (en) 2008-12-18
CN101198696B (zh) 2014-02-26
NZ561925A (en) 2010-04-30
EP1874928A1 (en) 2008-01-09
MX2007012704A (es) 2008-01-14
IL186036A0 (en) 2008-02-09
CA2602793A1 (en) 2006-10-19
JP2008535517A (ja) 2008-09-04
TWI384070B (zh) 2013-02-01
CA2602793C (en) 2016-11-22
KR20130140221A (ko) 2013-12-23
KR20080002949A (ko) 2008-01-04
BRPI0609120A2 (pt) 2010-11-16
ZA200708222B (en) 2008-11-26
WO2006110083A1 (en) 2006-10-19
US8304224B2 (en) 2012-11-06
AU2006234788A1 (en) 2006-10-19
CN101198696A (zh) 2008-06-11
TW200716753A (en) 2007-05-01
RU2007140550A (ru) 2009-05-20
RU2415934C2 (ru) 2011-04-10
KR101599062B1 (ko) 2016-03-02
AU2006234788B2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
AR053053A1 (es) Vector
WO2019126634A3 (en) Targeted integration of nucleic acids
CL2008003596A1 (es) Fitasa enzimaticamente susceptible, polinucleotido que la codifica, casete de expresion, vector y celula huesped que comprenden dicho acido nucleico; metodo de preparacion de la fitasa, y composiciones que la comprenden.
ATE530643T1 (de) Säureaktive fungale protease
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
CU23791A3 (es) Método para la producción de proteínas y anticuerpos mejorados
IN2012DN05169A (es)
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
MX2008002149A (es) Composiciones de arnt y sus usos.
DE602006019050D1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
EP2536821A4 (en) IMPROVING THE ACTIVITY OF PROTEINS REQUIRING AGGREGATE FE-S
WO2008114673A1 (ja) ポリペプチドの製造方法
CL2011003075A1 (es) Proteina precursora que comprende una secuencia repetitiva con propiedades de autoensamblaje que puede ser escindida en sus componentes, los que comprenden un peptido de interes y un peptido auxiliar de autoensamblaje; acido nucleico que la codifica; casete de expresion, vector; metodo de produccion; y su uso.
WO2008140582A3 (en) Production of anti-microbial peptides
AR062916A1 (es) Un sistema basado en facs y en proteinas informadoras para el desarrollo de alto rendimiento de proteinas terapeuticas
BRPI0810149A2 (pt) método para a produção de um hidrolisado de proteína de soro de leite, e, uso de um hidrolisado de proteína de soro de leite
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
WO2010118337A3 (en) Methods of enhancing yield of active iga protease
EA202091349A1 (ru) Способы культивирования клеток
WO2008121435A3 (en) Methods for generating novel stabilized proteins
CL2011003104A1 (es) Metodo para la elaboracion de acidos grasos no saturados, basado en el cultivo de una celula que expresa un polipeptido heterologo con actividad esaturasa/enoil-coa reductasa celula huesped, complejo elongasa que comprende dicho polipeptido y uso de la misma.
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
BRPI0913178A2 (pt) Método para produzir um hidrolisado de caseína, hidrolisado de caseína, e, uso de hidrolisado de caseína
WO2014170460A3 (en) Method for the production of collagen proteins derived from marine sponges and an organism able to produce said proteins
DK2296487T3 (da) Fremgangsmåde til fremstilling af et hvedeproteinhydrolysat

Legal Events

Date Code Title Description
FB Suspension of granting procedure